Kanazawa Ippei
Nihon Rinsho. 2015 Oct;73(10):1718-22.
Accumulating evidence has shown that the risk of osteoporotic fracture is increased in patients with type 1 and 2 diabetes mellitus. Measurement of bone mineral density is not a good evaluation tool for diabetes-related osteoporosis because the underlying mechanism is based on the deterioration of bone quality with accumulation of collagen cross-links of advanced glycation end products, decreased bone formation, and cortical porosity. Thus, we should choose the anti-osteoporosis drug while taking the mechanism into consideration. However, the evidence of treatments for diabetes-related osteoporosis is not sufficient so far. Therefore, further studies are necessary to solve this issue in future.
越来越多的证据表明，1型和2型糖尿病患者发生骨质疏松性骨折的风险会增加。骨密度测量并非评估糖尿病相关骨质疏松症的理想工具，因为其潜在机制是基于骨质量的恶化，这与晚期糖基化终产物的胶原交联积累、骨形成减少以及皮质骨孔隙率增加有关。因此，我们在选择抗骨质疏松药物时应考虑其作用机制。然而，目前关于糖尿病相关骨质疏松症治疗的证据尚不充分。所以，未来有必要开展进一步研究来解决这一问题。
